Full-Time

Medical Science Liaison

Immunology

Posted on 9/19/2025

Deadline 11/30/25
Amplity

Amplity

1-10 employees

Global contract services for drug lifecycle

No salary listed

Remote in Germany + 2 more

More locations: Remote in Spain | Remote in France

Remote

Home based in Germany, France, or Spain; 50-70% travel required.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • An advanced doctoral degree (MD, PhD, Pharm D) is preferred
  • Relevant therapeutic area knowledge in the field of immunology or immuno-oncology, experience in gastroenterology is a plus.
  • 3+ years of previous industry medical affairs experience required, preferably in MSL and/or headquartered based medical affairs role and clinical trial background
  • Fluency in English and local language
  • Demonstrable experience in building and maintaining relationships with KOLs
  • Ability to effectively communicate and assimilate scientific and clinical data to the relevant audience
  • Willing and able to travel internationally, up to ~ 70% of time
Responsibilities
  • Building and developing enduring relationships with HCPs, patient advocacy groups, professional societies, and institutions, creating constructive cross-functional partnerships with internal and external stakeholders
  • Serving as a primary interface between our client and clinical trial sites across all development programs, working closely with Clinical Development & Clinical Operations
  • Advising and participating in the planning and set-up of clinical studies
  • Representing our client at select scientific congresses and professional society meetings
  • Sharing important clinical and scientific insights that you have gathered from fieldwork to cross-functional teams
  • Acting as an internal and external scientific expert
  • Adhering to compliance requirements
  • Supporting investigator-initiated studies
Desired Qualifications
  • Post graduate therapeutic area experience is preferred
  • Biotech experience is a plus!

Amplity Health provides medical and commercial outsourcing services to pharmaceutical and healthcare companies across the full drug lifecycle. It uses an AI-driven platform and a HIPAA-compliant database to turn data into insights, while offering contract Medical Science Liaisons and patient support teams to engage with healthcare providers. The company combines data analytics, hands-on medical affairs execution, and a flexible, contract-based workforce to help clients scale as needed. Its goal is to speed up drug development, approvals, and market access while ensuring compliant data handling and efficient resource use.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$102.5M

Headquarters

Santa Cruz, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Christina DiBiase's April 2026 CEO appointment drives growth with 17 years experience.
  • Lynx Group 2022 acquisition expands medical communications and omnichannel marketing.
  • 40-year legacy specializes in oncology, rare diseases across 60 countries.

What critics are saying

  • IQVIA's 2025 IPM.ai acquisition erodes Amplity's oncology insights dominance.
  • FDA April 2026 AI guidance halts Ava and AskX deployments by 2027.
  • Ashfield poaches 15% of Amplity's oncology MSLs since January 2026.

What makes Amplity unique

  • Amplity Insights™ analyzes 70 million doctor-patient records to reveal treatment decision 'whys'.
  • In Practice platform delivers oncology intelligence for community oncologists since 2026.
  • Ava AI chatbot enhances personalized digital experiences on Amplity.com.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Company News

The News Courier
Mar 26th, 2026
Peritia appoints Michael A. Griffith as Chief Executive Officer.

Peritia appoints Michael A. Griffith as Chief Executive Officer. PR Newswire Today at 4:00am PDT Veteran life sciences executive and platform builder brings decades of biopharma leadership to accelerate growth. MORRISVILLE, N.C. and NEW YORK, March 26, 2026 /PRNewswire/ - Peritia, a global biopharmaceutical and medtech consulting company with deep expertise in clinical development and value and evidence generation, today announced the appointment of Michael Griffith as Chief Executive Officer. Mr. Griffith brings more than 25 years of executive leadership experience to build and scale global pharmaceutical services businesses, and his appointment marks a significant milestone in Peritia's evolution. A Platform Builder with Proven Impact Most recently, Mike served as founder and CEO of Amplity Health, a global contract medical and commercial organization operating across 40 countries with more than 1,000 colleagues. Prior to Amplity, he served as Operating Partner at Altamont Capital Partners, where he led investments in biopharmaceutical outsourcing businesses, and as President of the Commercial Division of inVentiv Health, a leading global provider of biopharmaceutical outsourcing services across the research and commercialization continuum. His career also includes CEO stints at ChiRex, Aptuit, and Laureate Biopharma - each a recognized leader in contract drug development and manufacturing - as well as board service at Repligen Corporation and other public life sciences companies. He holds a Master of Management degree from Northwestern University's Kellogg School of Management. "As biopharma and medtech innovator funding continues to build, Peritia is exactly the kind of platform the industry needs right now - one that combines scientific depth, strategic advisory, and operational capability to our client engagements," said Mike Griffith. Peritia has successfully completed more than 1,100 engagements in 20 countries for 355 clients in the past five years. "Now we have the opportunity to scale the enterprise with purpose by building on the strong foundation that's already been established. Our goal is to be a trusted partner for biotech, pharma, and medtech innovators who require additional power to navigate clinical development and health economics." Griffith's appointment comes on the heels of Peritia's formal rebranding and consolidation of BioBridges, CHEORS, and Monitorforhire into a unified platform spanning corporate and product strategy, operational execution, and value, evidence, and access. His track record of building high-performance cultures and scaling life sciences service organizations positions him to accelerate Peritia's mission of guiding life sciences organizations from concept to commercialization. For media inquiries or to learn more about how Peritia can support your programs, please contact us at us at [email protected] or visit www.peritia.com, or visit our LinkedIn page at https://www.linkedin.com/company/peritiaholdings/ About Peritia Peritia is a global biopharmaceutical and medtech consulting company specializing in clinical development and value and evidence generation. We connect industry-leading talent with organizations across the life sciences ecosystem to help bring innovations to patients efficiently and effectively. In the last five years, Peritia has completed more than 1,100 engagements for 335 clients worldwide. Peritia \puh-rish-uh\ noun: the state or quality of being experienced. SOURCE Peritia This is a paid placement. For further inquiries, please contact PR Newswire directly.

Amplity
Jul 10th, 2025
Amplity Rebrand Earns Prestigious Industry Awards

The Titan Awards, an international advertising competition recognizing extraordinary achievements in healthcare advertising and marketing, honored Amplity as a Platinum Winner for Best Rebranding Effort and a Gold Winner for Best Website Design.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

Amplity
May 28th, 2025
Meet Ava: Amplity's AI Chatbot Enhancing Web UX

Amplity, a full-service partner for outsourcing flexible medical and commercial services, proudly announces the launch of Ava, an AI-powered chatbot designed to deliver faster, more personalized digital experiences on Amplity.com.

Amplity
May 15th, 2025
Amplity Unveils GLP-1 RAs & Biologic Trends At ISPOR 2025

Amplity unveils GLP-1 RAs & biologic trends at ISPOR 2025.

INACTIVE